N-Benzyl-methyl-3 morpholin | 32730-44-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-Benzyl-methyl-3 morpholin
• 英文别名: 4-benzyl-3-methylmorpholine
• CAS: 32730-44-2；74571-98-5；120800-91-1
• 化学式: C₁₂H₁₇NO
• mdl: MFCD22548229
• 分子量: 191.273
• InChiKey: GXNBKAFYCHTQPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (2-Allyloxy-ethyl)-benzyl-amine 在 silver tetrafluoroborate 、 C₃₆H₂₆I₂N₄Pt 作用下， 以 苯 为溶剂， 反应 48.0h， 以90%的产率得到N-Benzyl-methyl-3 morpholin
  参考文献：
  名称：

  A N-heterocyclic carbene (NHC) platinum complex as pre-catalyst for the intramolecular hydroamination of olefins with secondary alkylamines and oxidative amination of ω-alkenic amines

  摘要：

  A N-heterocyclic carbene (NHC) platinum complex 3 prepared from BINAM was found to be a highly effective pre-catalyst for the intramolecular hydroamination of olefins with secondary alkylamines to give the corresponding intramolecular hydroamination products in excellent yields. The substrate scope has been carefully examined and the plausible reaction mechanism has been also proposed. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2012.02.060

文献信息

• Phthalazine, aza- and diaza-phthalazine compounds and methods of use
  申请人：Tasker Andrew

  公开号：US20060199817A1

  公开（公告）日：2006-09-07

  The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A 1 , A 2 , B, R 1 , R 2 , R 3 and R 4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.

  本发明包括一类新的化合物，用于预防和治疗蛋白激酶介导的疾病，包括炎症及相关状况。这些化合物的通用公式为I 其中A 1 ，A 2 ，B，R 1 ，R 2 ，R 3 和R 4 在此定义。该发明还包括包括一个或多个I公式化合物的药物组合物，以及使用这些化合物和组合物治疗激酶介导的疾病，包括类风湿性关节炎，银屑病和其他炎症性疾病，以及用于制备I公式化合物的中间体和工艺。
• [EN] CONJUGATES COMPRISING RIPK2 INHIBITORS<br/>[FR] CONJUGUÉS COMPRENANT DES INHIBITEURS DE RIPK2
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017182418A1

  公开（公告）日：2017-10-26

  The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of RIP2 kinase, including degrading RIP2 kinase, the treatment of diseases and conditions mediated by the RIP2 kinase, in particular for the treatment of inflammatory diseases or conditions.

  本发明涉及化合物、组合物、组合物和含有所述化合物的药物以及其制备方法。该发明还涉及所述化合物、组合物、组合物和药物的用途，例如作为RIP2激酶活性的抑制剂，包括降解RIP2激酶，用于治疗由RIP2激酶介导的疾病和症状，特别是用于治疗炎症性疾病或症状。
• 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS
  申请人：Yang Zhicai

  公开号：US20080255114A1

  公开（公告）日：2008-10-16

  Compounds of formulae I, II and III: are disclosed as 5-HT3 inhibitors. The compounds are useful in treating CINV, IBS-D and other diseases and conditions.

  化学式I、II和III的化合物被披露为5-HT3受体拮抗剂。这些化合物在治疗化疗诱发恶心呕吐综合征（CINV）、腹泻型肠易激综合征（IBS-D）和其他疾病和症状中很有用。
• [EN] FUSED RING COMPOUND AS FGFR AND VEGFR DUAL INHIBITOR<br/>[FR] COMPOSÉ CYCLIQUE FUSIONNÉ EN TANT QU'INHIBITEUR DOUBLE DE FGFR ET VEGFR<br/>[ZH] 作为FGFR和VEGFR双重抑制剂的并环类化合物
  申请人：MEDSHINE DISCOVERY INC

  公开号：WO2020249096A1

  公开（公告）日：2020-12-17

  一种作为FGFR和VEGFR双重抑制剂的并环类化合物，具体公开了式(III)所示化合物或药学上可接受的盐。
• Bresson,A. et al., Bulletin de la Societe Chimique de France, 1971, p. 1080 - 1087
  作者：Bresson,A. et al.

  DOI：——

  日期：——